The staphylococci in general, and S. aureus in particular, are the most prominent bacterial pathogens causing musculoskeletal infection. These infections are remarkably difficult to treat. This is due to a number of factors including the failure to detect the infection until it has progressed to a chronic infection characterized by formation of necrotic bone, the continued emergence of antibiotic resistance among the staphylococci, which are the preeminent musculoskeletal pathogens, and the inability to deliver effective concentrations of the most appropriate antibiotic to the site of infection. These three issues are the experimental focus of this proposal. Specifically, the aims of this proposal are:
Aim 1 : To optimize FDG-PET for the early detection of musculoskeletal infection.
This aim i s based on our belief that we can increase the specificity of FDG-PET without an unacceptable sacrifice of sensitivity by optimizing methods of data acquisition and analysis in the specific context of musculoskeletal infection vs. other forms of inflammation. We will evaluate this hypothesis using an established rabbit model of postsurgical osteomyelitis.
Aim 2 : To develop a rapid diagnostic method that will facilitate determinative antimicrobial therapy of staphylococcal musculoskeletal infection. We will build on previous experiments in the Pi's laboratory to develop PCR-based methods that address the most critical therapeutic issues and can be used for the direct analysis of clinical samples without the need for cultural amplification.
Aim 3 : To optimize antibiotic therapy for biofilm-associated musculoskeletal infection. We will use our rabbit osteomyelitis model to determine the optimal method of delivering the most commonly used anti-staphylococcal agents directly to the site of infection. We will also evaluate the utility of FDG-PET as a means of monitoring the response to antimicrobial therapy. Lay description: Staphylococcus aureus is the most common pathogen causing devastating bone and joint infection. These infections are very difficult to treat and often require surgery or even amputation. The goals of our work are to enhance the detection, diagnosis and treatment of these infections. While the experiments we propose will focus on S. aureus, the results will be applicable to other bacterial pathogens that cause musculoskeletal infection. The results will also be applicable to patient care in that they will ultimately form the basis for clinical recommendations regarding these critical diagnostic and treatment issues. This is consistent with the NIH Roadmap emphasis on """"""""bench-to-bedside"""""""" translational research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI069087-04
Application #
7761272
Study Section
Special Emphasis Panel (ZRG1-IDM-A (02))
Program Officer
Huntley, Clayton C
Project Start
2007-02-01
Project End
2012-01-31
Budget Start
2010-02-01
Budget End
2011-01-31
Support Year
4
Fiscal Year
2010
Total Cost
$344,481
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Beenken, Karen E; Smith, James K; Skinner, Robert A et al. (2014) Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis. J Biomater Appl 29:514-23
Beenken, Karen E; Mrak, Lara N; Zielinska, Agnieszka K et al. (2014) Impact of the functional status of saeRS on in vivo phenotypes of Staphylococcus aureus?sarA mutants. Mol Microbiol 92:1299-312
Zielinska, Agnieszka K; Beenken, Karen E; Mrak, Lara N et al. (2012) sarA-mediated repression of protease production plays a key role in the pathogenesis of Staphylococcus aureus USA300 isolates. Mol Microbiol 86:1183-96
Beenken, Karen E; Bradney, Laura; Bellamy, William et al. (2012) Use of xylitol to enhance the therapeutic efficacy of polymethylmethacrylate-based antibiotic therapy in treatment of chronic osteomyelitis. Antimicrob Agents Chemother 56:5839-44
Brown, Tracy L Y; Spencer, Horace J; Beenken, Karen E et al. (2012) Evaluation of dynamic [18F]-FDG-PET imaging for the detection of acute post-surgical bone infection. PLoS One 7:e41863
Quave, Cassandra L; Estévez-Carmona, Miriam; Compadre, Cesar M et al. (2012) Ellagic acid derivatives from Rubus ulmifolius inhibit Staphylococcus aureus biofilm formation and improve response to antibiotics. PLoS One 7:e28737
Hobby, Gerren H; Quave, Cassandra L; Nelson, Katie et al. (2012) Quercus cerris extracts limit Staphylococcus aureus biofilm formation. J Ethnopharmacol 144:812-5
Ordóñez, Paola E; Quave, Cassandra L; Reynolds, William F et al. (2011) Sesquiterpene lactones from Gynoxys verrucosa and their anti-MRSA activity. J Ethnopharmacol 137:1055-9
Smith, J Keaton; Bumgardner, Joel D; Courtney, Harry S et al. (2010) Antibiotic-loaded chitosan film for infection prevention: A preliminary in vitro characterization. J Biomed Mater Res B Appl Biomater 94:203-11
Harik, Nada S; Smeltzer, Mark S (2010) Management of acute hematogenous osteomyelitis in children. Expert Rev Anti Infect Ther 8:175-81

Showing the most recent 10 out of 13 publications